CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Complete Title: A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors

Trial Phase: I

Investigator: Jennifer Specht

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

Keywords:

Bile Duct Cancer
Bladder Cancer
Endometrial Cancer
Head and Neck Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Stomach Cancer
HER2-Positive
Lung Carcinoma, Non-Small-Cell (NSCLC)
Adenocarcinoma
Colorectal Neoplasms
Carcinoma, Ductal
Carcinoma, Hepatocellular
Neoplasms, Squamous Cell
Lung Carcinoma, Small-Cell
Biliary Tract Neoplasms
Gastroesophageal Junction Cancer
Carcinoma, Transitional Cell
Carcinoma, Small Cell
Neoplasms, Malignant
HER2

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.